GSK PLC-SPON ADR.
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding GSK's stock, with a target price indicating potential decline.
Financial Health
GSK is performing well with strong revenue and profit generation, although cash flow may need improvement.
Dividend
GSK's average dividend yield of 4.25% makes it a reasonable choice for dividend-seeking investors. If you invested $1000 you would be paid $42.50 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GSK
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketNovo Nordisk Stock Risks: Healthcare Diversification
As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.
Published: September 23, 2025
Explore BasketJohnson & Johnson (Healthcare Diversification)
As Nigeria's population seeks stable growth opportunities, the global healthcare sector offers a compelling theme for portfolio diversification. This basket provides exposure through a collection of US and EU-listed industry leaders in pharmaceuticals, medical devices, and consumer health.
Published: September 16, 2025
Explore BasketPharma Investment Basket Explained (Eli Lilly+)
Nigeria's growing population is increasingly seeking exposure to global health advancements, particularly from leading pharmaceutical innovators. This basket provides potential exposure to this trend through a collection of US and EU-listed pharmaceutical, biotechnology, and healthcare supply chain companies.
Published: September 11, 2025
Explore BasketObesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: September 10, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketDefensive Plays For A Slowing Economy
U.S. job growth has slowed more than expected, signaling that economic uncertainty from trade tensions is impacting the labor market. This creates a potential investment opportunity in companies that are resilient to economic headwinds, such as those in defensive sectors and essential business services.
Published: August 4, 2025
Explore BasketPharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: August 3, 2025
Explore BasketBeyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: August 1, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketBuffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: July 1, 2025
Explore BasketBoomer Stocks
Discover a collection of iconic, industry-leading companies with deep market roots and reliable dividend histories. These household names have been carefully selected by our analysts for their strong brands, steady cash flow, and potential for long-term stability.
Published: June 17, 2025
Explore BasketMade in the UK
Diversify your portfolio with some of Britain's most established companies. Our analysts have carefully selected these UK powerhouses that span multiple industries from banking to pharmaceuticals, energy to consumer goods.
Published: May 10, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketUK-US Trade Deal
These carefully selected UK stocks could benefit from the newly announced US-UK trade agreement, the first under Trump's second administration. Our professional analysts have identified companies with potential upside as tariffs are cut on British exports like steel, aluminum, and more.
Published: May 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Late-stage trials and approvals can change growth prospects, though clinical setbacks are possible and can affect share value.
Vaccines & R&D
A strong vaccines franchise supports revenue potential, but R&D outcomes are uncertain and require close monitoring.
Global Reach & Risks
Exposure to international markets diversifies sales but brings currency, regulatory and geopolitical risks that can impact performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Eli Lilly and Company
Eli Lilly & Co is a global pharmaceutical company that develops, manufactures and markets human prescription drugs.
Johnson & Johnson
Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
